|
Market Closed -
Nasdaq
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 19.90 USD | +0.25% |
|
-4.51% | +28.97% |
| 09-04 | Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says | MT |
| 08-10 | Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating | MT |
| Market Cap | 1.27B 1.09B 1.02B 934M 1.75B 120B 1.75B 12.14B 4.69B 61.29B 4.75B 4.65B 195B | P/E 2026 * |
-6.81x | P/E 2027 * | -6.94x |
|---|---|---|---|---|---|
| Enterprise Value | 920M 791M 744M 679M 1.27B 87B 1.27B 8.82B 3.41B 44.55B 3.45B 3.38B 142B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
99.21% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| JBIO | Delayed | |
CBOE
| JBIO | Real-time |
Last Transcript : Jade Biosciences, Inc.
| 1 day | +0.25% | ||
| 1 week | -4.51% | ||
| Current month | -6.84% | ||
| 1 month | -10.52% | ||
| 3 months | +17.47% | ||
| 6 months | +41.64% | ||
| Current year | +28.97% |
| 1 week | 19.7 |  | 22 |
| 1 month | 19.7 | | 25 |
| Current year | 12.45 | | 28 |
| 1 year | 6.91 | | 28 |
| 3 years | 6.56 | | 28 |
| 5 years | 6.56 | | 28 |
| 10 years | 6.56 | | 28 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tom Frohlich
CEO | Chief Executive Officer | 50 | 2025-04-27 |
Bradford Dahms
DFI | Director of Finance/CFO | 38 | 2025-07-13 |
Sandy Lewis
CTO | Chief Tech/Sci/R&D Officer | - | 2024-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Tom Frohlich
BRD | Director/Board Member | 50 | 2025-04-27 |
Christopher Cain
BRD | Director/Board Member | 42 | 2025-04-27 |
Eric Dobmeier
CHM | Chairman | 57 | 2025-04-27 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/25/26 | Free | Director | 47,675 | 0.0966% | ||
| 2/12/26 | Free | General Counsel | 196,875 | 0.4280% | ||
| 2/12/26 | Free | Chief Technology Officer | 288,750 | 0.6277% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.25% | -4.51% | +156.11% | - | 1.27B | |
| -1.16% | -3.97% | -2.91% | +13.00% | 48.93B | |
| -0.40% | +1.03% | +418.57% | +527.30% | 45.01B | |
| -1.42% | +2.30% | +42.67% | +22.37% | 44.07B | |
| -1.22% | -2.31% | +4.82% | +77.49% | 40.73B | |
| -0.96% | -2.31% | +15.75% | +45.41% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +21.42% | +120.75% | 16.5B | |
| -1.54% | -1.05% | +12.16% | +29.80% | 14.67B | |
| -1.65% | -1.03% | +75.93% | +41.12% | 13.77B | |
| Average | -0.84% | -0.02% | +82.72% | +109.66% | 27.63B | |
| Weighted average by Cap. | -0.94% | +0.03% | +89.29% | +128.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -204M -176M -165M -151M -282M -19.31B -283M -1.96B -757M -9.89B -767M -750M -31.5B | -231M -199M -187M -171M -319M -21.86B -320M -2.22B -857M -11.19B -868M -849M -35.66B |
| Net Debt | -346M -297M -280M -255M -477M -32.69B -479M -3.32B -1.28B -16.74B -1.3B -1.27B -53.33B | -354M -304M -286M -261M -488M -33.45B -490M -3.39B -1.31B -17.13B -1.33B -1.3B -54.57B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | US$19.90 | +0.25% | 605,018 |
| 26-09-03 | US$19.85 | -7.24% | 1,381,784 |
| 26-09-02 | US$21.40 | +1.81% | 506,170 |
| 26-09-01 | US$21.02 | -1.59% | 516,638 |
| 26-08-31 | US$21.36 | +2.50% | 837,036 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- JBIO Stock
Select your edition
All financial news and data tailored to specific country editions
